PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
REGULATORY
Scrap Coverage for OTC-Like Drugs with Same APIs and Dose as OTC Meds: Nippon Ishin
The opposition Japan Innovation Party (Nippon Ishin) is calling for eliminating insurance coverage for OTC-like drugs, starting with those with the same APIs and maximum daily dose as OTC medicines. Nippon Ishin lawmaker Naoki Inose presented the proposal at an…
To read the full story
Related Article
- Ruling Bloc, Ishin Agree to Discuss Coverage of OTC-Like Drugs
June 12, 2025
- 3 Parties Agree to Review OTC-Like Drugs from FY2026, but Details Still in the Air
June 9, 2025
- Ishin Nixes Ruling Bloc’s Draft Social Security Plans over OTC-Like Drug Issue
May 30, 2025
- Topic of OTC-Like Drugs Dropped from 3-Party Talks: Ishin
May 27, 2025
- Impact of Nationwide Implementation of Regional Formularies “Difficult to Estimate”: MHLW Official
May 23, 2025
- OTC-Like Drug Is Hardest Topic in Tripartite Social Security Talks: Japan PM
May 22, 2025
- Regional Formulary Push Pops Up from Ishin at 3-Party Talks
May 16, 2025
- Ruling Bloc, Ishin Reach No Deal on Coverage of OTC-Like Drugs
May 8, 2025
- MHLW to Present Estimate on Coverage Removal of OTC-Like Meds at 3-Party Talks
April 24, 2025
- Ruling Coalition Wary of Scrapping Coverage for OTC-Like Drugs
April 21, 2025
- Medical Advocacy Group Condemns Plan to Remove Coverage for OTC-Like Drugs
April 17, 2025
- 3-Party Talks Fail to Reach Specifics on OTC-Like Drugs
April 4, 2025
- Three-Party Talks to Be Held on Health Coverage of OTC-Like Drugs: Minister
March 4, 2025
REGULATORY
- MHLW to Discuss Faster MCM Approvals during Health Emergencies
October 26, 2026
- Foreign Price Adjustment Rule a Key Issue in Japan’s MFN Response: Official
October 26, 2026
- MHLW Official Vows Crackdown on Illegal Mounjaro Sales
October 26, 2026
- Temodal, Topotecin Gain NHI Coverage for Neuroblastoma Combo Therapy
October 26, 2026
- Japan Approves OTC Version of Taiho’s Allergy Drug Bilanoa
October 26, 2026
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…